12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vascepa icosapent ethyl regulatory update

Amarin said FDA accepted its sNDA for Vascepa icosapent ethyl as an adjunct to diet to treat adult patients with high triglycerides, defined as triglyceride levels of >=200 mg/dL and <500 mg/dL, with mixed dyslipidemia. The PDUFA date...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >